

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 4

TRIANGLE PHARMACEUTICALS INC
 Form 4
 April 10, 2001

 FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549

// CHECK THIS BOX IF NO LONGER SUBJECT TO SECTION 16. FORM 4 OR FORM 5 OBLIGATIONS MAY CONTINUE. SEE INSTRUCTION 1(b).
 (Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 Section 17(a) of the Public Utility Holding Company Act of 1935
 Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fleming Standish M. (Last) (First) (Middle) c/o Forward Ventures 9255 Towne Centre Drive, Suite 300 (Street) San Diego CA 92121 (City) (State) (Zip)	2. Issuer Name AND Ticker or Trading Symbol Triangle Pharmaceuticals, Inc. (VIRS) 3. IRS or Social Security Number of Reporting Person (Voluntary) 4. Statement for Month/Year March 2001 5. If Amendment, Date of Original (Month/Year)	6. R X -- --- 7. /X/ / /
--	---	--

TABLE I - NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR TRANSFERRED					
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	(A) or (D)	Amount or Price (Instr. 4 and 5)
Common Stock					106,082
Common Stock					817
Common Stock					1,545
Common Stock					4,122
Common Stock					520,000
Common Stock					233,663

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 4

Series B Convertible Preferred Stock	3/8/2001	P	120,704	A	\$60	120,704
Series B Convertible Preferred Stock	3/8/2001	P	12,629	A	\$60	12,629

* If the form is filed by more than one reporting person, SEE Instruction 4(b)(v).
 Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

FORM 4 (CONTINUED) TABLE II - DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIAL
(E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		
			Code	V	(A)	(D)

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 4

7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Month (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Title	Amount or Number of Shares			

Explanation of Responses:

- (+) Mr. Fleming disclaims beneficial ownership of these shares other than to the extent of his pecuniary interests.
- (1) Represents a distribution of 3,082 shares made by Forward II Associates, L.P., of which Mr. Fleming received 656 shares in his individual capacity.
In prior reports, Mr. Fleming has reported beneficial ownership of the distributed shares.
- (2) Represents shares held by the Fleming Family Trust, of which Mr. Fleming is a co-trustee.
- (3) Represents shares held by the Fleming Family Children's Trust, of which Mr. Fleming is a co-trustee.
- (4) Represents all shares held by Forward II Associates, L.P. (to the extent of its own partnership interest in Forward II, L.P.).
- (5) Represents all shares held by Forward Ventures II, L.P.
- (6) Represents all shares held by Forward Ventures III, L.P., of which Forward III Associates, L.P., of which Mr. Fleming is a managing member.
- (7) Represents all shares held by Forward Ventures IV, L.P., of which Forward IV Associates, L.P., of which Mr. Fleming is a managing member.
- (8) Represents all shares held by Forward Ventures IV B, L.P., of which Forward IV Associates, L.P., of which Mr. Fleming is a managing member.

/s/ Standish

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**Signature of

Note: File three copies of this Form, one of which must be manually signed.
If space is insufficient, SEE Instruction 6 for procedure.

